H

ello, everyone, and how are you today? We are just fine, thank you, despite a bit of road lag after taking a late-night drive to the town where our corporate nerve center is located. A change of pace is a good thing, of course, although we must now forage for cups of stimulation. Then again, this could be an adventure. Speaking of which, the news is always full of adventure. To prove the point, here are some tidbits. Hope your day is delightful and do keep in touch …

An Axovant Sciences (AXON) pill being tested to blunt Alzheimer’s failed in a late-stage clinical trial, STAT tells us. In the study involving more than 1,300 patients with mild to moderate Alzheimer’s, the combination of intepirdine and Aricept failed to outpace the older drug alone, missing key goals of improving memory and physical function. The news wiped out about 70 percent of its market value in early-morning trading. The drug maker was worth more than $2.6 billion before the news of the failure.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Inteperdine should never have reached Phase 3. The intent-to-treat analysis is the gold standard, and was not positive in previous study. This would normally be a “no go” signal at end of phase 2, but these failed studies will continue as long as drug makers see AZ as the proverbial pot of gold.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy